Guerbet SA (Guerbet) manufactures contrast agents. Its products find application in diagnostic purposes, including X-ray examinations, magnetic resonance imaging (MRI), and nuclear medicine. These agents are administered to patients primarily by injection. Its X-ray imaging contrast agents consist of iodinated active substances and barium-based products. MRI imaging uses gadolinium complexes. In nuclear medicine, radioactive agents are used for diagnostic purposes. The company operates through a single operating segment: the research, development, production, and sale of contrast media for medical imaging. The company classifies its product portfolio into two categories, namely, Diagnostic Imaging and Interventional Imaging. Guerbet operates eight specialized manufacturing facilities for high-performance industrial production, comprising three sites, including Lanester, Marans and Dublin for the manufacture of active pharmaceutical ingredients (APIs); three fill-and-finish facilities for contrast agents; and two sites dedicated to imaging solutions (injectors, disposables) and services.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Guerbet's research objective is to offer radiology professionals and patients safe and innovative solutions consisting of drugs and medical devices, including software solutions. The company's R&D activities are focused on Diagnostic Imaging and Interventional Imaging. The company is also researching in the three main therapeutic areas of oncology, cardiology, and neurology. The R&D units of Guerbet are organized into four departments: development & engineering, accurate medical therapeutics, augmented intelligence, and research & innovation. The development & engineering team specializes in the development of medical devices. Accurate medical therapeutics focuses on the development of interventional medical devices. The augmented intelligence team is responsible for the research and development of augmented intelligence solutions. The research & innovation team is involved in research and innovation in pharmaceuticals and medical devices and manages the patent portfolio. The company is also involved in R&D activities on gadopiclenol in partnership with Bracco Imaging, with new clinical studies underway. Additionally, Guerbet SA is focusing on strengthening its leadership in MRI, developing Lipiodol for new therapeutic applications, and expanding its AI solutions for oncology. The company operates 4 R&D centers across Europe and North America, holds more than 516 patents. In FY2024, the company incurred research and development expenses of EUR12.8 million. Accounted for 9% of the company’s revenue.